Clinical characteristics and cytokine profiles for early prediction of severe Mycoplasma pneumoniae pneumonia in children: a prospective cohort study - Scorecard - MDSpire
Advertisement
Clinical characteristics and cytokine profiles for early prediction of severe Mycoplasma pneumoniae pneumonia in children: a prospective cohort study
Clinical Scorecard: Early Identification of Severe Mycoplasma pneumoniae Pneumonia in Pediatric Patients: A Prospective Study on Clinical Features and Cytokine Profiles
At a Glance
Category
Detail
Condition
Mycoplasma pneumoniae pneumonia (MPP)
Key Mechanisms
Excessive immune responses and pro-inflammatory cytokine release during Mycoplasma pneumoniae infection.
Target Population
Children diagnosed with Mycoplasma pneumoniae pneumonia.
Care Setting
Pediatric Respiratory Medicine
Key Highlights
57.3% of children with MPP developed severe Mycoplasma pneumoniae pneumonia (SMPP).
Independent risk factors for SMPP include wheezing, shortness of breath, fever, D-dimer, CRP, and age.
A predictive nomogram for early identification of SMPP was established with an AUC of 0.818.
Guideline-Based Recommendations
Diagnosis
Diagnosis of MPP requires clinical manifestations or radiological evidence and serological or pathogen testing.
Management
Focus on early identification of severe disease to improve treatment efficacy.
Monitoring & Follow-up
Dynamic monitoring of cytokines is significant for understanding disease progression.
Risks
Severe cases can lead to acute respiratory distress syndrome.
Patient & Prescribing Data
Children aged 5 and under, with a significant proportion of CAP cases attributable to Mycoplasma pneumoniae.
Elevated serum cytokines in SMPP patients indicate potential clinical utility for monitoring.
Clinical Best Practices
Utilize a predictive nomogram for risk stratification in hospitalized children with MPP.
Monitor clinical features and laboratory parameters closely to identify severe cases early.
